摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(benzyloxy)-2-(tert-butyl)aniline | 1352342-91-6

中文名称
——
中文别名
——
英文名称
4-(benzyloxy)-2-(tert-butyl)aniline
英文别名
2-tert-butyl-4-phenylmethoxyaniline
4-(benzyloxy)-2-(tert-butyl)aniline化学式
CAS
1352342-91-6
化学式
C17H21NO
mdl
——
分子量
255.36
InChiKey
QRYQRDIGTMPNGZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.4
  • 重原子数:
    19
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.29
  • 拓扑面积:
    35.2
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] AMINO QUINOLINE DERIVATIVES INHIBITORS OF HCV<br/>[FR] DÉRIVÉS D'AMINO-QUINOLÉINE INHIBITEURS DE VHC
    申请人:GILEAD SCIENCES INC
    公开号:WO2013090929A1
    公开(公告)日:2013-06-20
    A compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents are defined herein, and methods of treating HCV infection in a patient are disclosed.
    一种化合物的化学式I:或其药用可接受的盐,其中取代基在此定义,并公开了治疗患者HCV感染的方法。
  • NHC‐Catalyzed Desymmetrization of N‐Aryl Maleimides Leading to the Atroposelective Synthesis of N‐Aryl Succinimides
    作者:Soumen Barik、Sayan Shee、Soumik Das、Rajesh G. Gonnade、Garima Jindal、Subrata Mukherjee、Akkattu T. Biju
    DOI:10.1002/anie.202016938
    日期:2021.5.25
    leading to the atroposelective synthesis of biaryls and allied compounds are well‐known, the related synthesis of compounds bearing axially chiral C−N bonds are relatively rare. Described herein is the Nheterocyclic carbene‐catalyzed atroposelective synthesis of N‐aryl succinimides having an axially chiral C−N bond via the desymmetrization of N‐aryl maleimides. The NHC involved intermolecular Stetter‐aldol
    尽管导致手性C-C键的轴向合成导致联芳基和相关化合物的对映选择性合成是众所周知的,但带有轴向手性C-N键的化合物的相关合成却相对较少。本文描述的是通过N-芳基马来酰亚胺的去对称化作用,对具有轴向手性C-N键的N-芳基琥珀酰亚胺进行N-杂环卡宾催化的对位选择性合成。NHC涉及分子间的二醛与前手性N-芳基马来酰亚胺的分子间Stetter-aldol级联反应,然后氧化得到N-芳基琥珀酰亚胺,具有良好的收率和ee值。还提供了有关C–N键的旋转势垒,温度依赖性的初步研究,以及有关机理的详细DFT研究。
  • PHENYL/PYRIDYL-N-PHENYL/PYRIDYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION
    申请人:ABIVAX
    公开号:EP3820850A1
    公开(公告)日:2021-05-19
  • ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION
    申请人:ABIVAX
    公开号:US20210122732A1
    公开(公告)日:2021-04-29
    A compound of formula (Ie): wherein Y 1 represents an aryl group, X 2 represents a —O— group, a —NH— group, a —S— group, a —CO—NH— group, a —NH—CO—NH— group, a —NH—CO— group, a —CH(OH)— group, a —CH(COOH)NH— group, a —CH(COOCH 3 )NH— group, a —C(OH)(CH 2 OH)—, a group, a divalent 5-membered heteroaromatic ring comprising 1, 2, 3 or heteroatoms, a —SO 2 — group, or a —SO 2 —NH— group, Y 2 represents a hydrogen atom, a hydroxyl group, a (C 1 -C 4 )alkoxy group, a —CHC(OH) 2 , a COOR f , wherein R f represents a hydrogen atom or a (C 1 -C 4 )alkyl group, a morpholinyl group, a dihydropyranyl group, a group, a group, a —PO(OR f )(OR′ f ) group, wherein R f and R′ f independently represents a hydrogen atom or a (C 1 -C 4 )alkyl group, an oxetanyl group, a —Si(CH 3 ) 3 group, a —NHCOO—(C 1 -C 4 )alkyl group, or a —CR 1 R 2 R 3 group, or any of its pharmaceutically acceptable salt and pharmaceutical compositions containing them and to synthesis process for manufacturing them.
  • [EN] PHENYL/PYRIDYL-N-PHENYL/PYRIDYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION<br/>[FR] DÉRIVÉS DE PHÉNYLE/PYRIDYLE-N-PHÉNYLE/PYRIDYLE POUR LE TRAITEMENT D'UNE INFECTION PAR UN VIRUS À ARN
    申请人:ABIVAX
    公开号:WO2020011816A1
    公开(公告)日:2020-01-16
    The present invention relates to a compound of formula (Ie) wherein Y1 represents an aryl group, X2 represents a -O- group, a -NH- group, a -S- group, a-CO-NH- group, a -NH-CO-NH- group, a -NH-CO- group, a -CH(OH)- group, a -CH(COOH)NH- group, a -CH(COOCH3)NH- group, a -C(OH)(CH2OH)-, a (AA) group, a divalent 5-membered heteroaromatic ring comprising 1, 2, 3 or heteroatoms, a -SO2- group, or a -SO2-NH- group, Y2 represents a hydrogen atom, a hydroxyl group, a (C1-C4)alkoxy group, a -CHC(OH)2, a COORf, wherein Rf represents a hydrogen atom or a (C1-C4)alkyl group, a morpholinyl group, a dihydropyranyl group, a (BB) group, a (CC) group, a -PO(ORf)(OR'f) group, wherein Rf and R'f independently represents a hydrogen atom or a (C1-C4)alkyl group, an oxetanyl group, a -Sί(CH3)3 group, a -NHCOO-(C1-C4)alkyl group, or a -CR1R2R3 group, or any of its pharmaceutically acceptable salt. The present invention further relates to pharmaceutical compositions containing them and to synthesis process for manufacturing them.
查看更多